Eligibility, Utilization, and Effectiveness of 17-Alpha Hydroxyprogesterone Caproate in a Statewide Population-Based Cohort of Medicaid Enrollees.

Wang, Xi; Garcia, Stephanie M; Kellom, Katherine S; Boelig, Rupsa C; Matone, Meredith

Wang, Xi; Garcia, Stephanie M; Kellom, Katherine S; Boelig, Rupsa C; Matone, Meredith.

Afiliación

Wang X; PolicyLab, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Garcia SM; PolicyLab, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Kellom KS; PolicyLab, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Boelig RC; Department of Obstetrics and Gynecology, Department of Pharmacology and Experimental Therapeutics, Division of Maternal Fetal Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.
Matone M; PolicyLab, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

Am J Perinatol ; 40(16): 1770-1780, 2023 12.

Article en En | MEDLINE | ID: mdl-34784617

Asunto(s)

Nacimiento Prematuro; Embarazo; Femenino; Recién Nacido; Humanos; Caproato de 17 alfa-Hidroxiprogesterona/uso terapéutico; Nacimiento Prematuro/epidemiología; Nacimiento Prematuro/prevención & control; Hidroxiprogesteronas/uso terapéutico; Medicaid; Estudios Retrospectivos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Nacimiento Prematuro Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Newborn / Pregnancy Idioma: En Revista: Am J Perinatol Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google